Several reports indicate that GlaxoSmithKline (NYSE: GSK) will buy Human Genome Sciences (NASDAQ: HGSI) for $2.8 billion. The two companies have battled over the price for several months. GSK believes it needs the latest biotech products and research to offset the slow growth a number of big pharma companies have experienced as many of their blockbuster drugs come off patent. To close the transaction, GSK increased its offer to $14 a share from $13. Reuters reports:
“It looks like a great conclusion for Glaxo. At around $14 a share, it is marginally higher than they first pitched but lower than I expected them to have to pay,” said Navid Malik, an industry analyst at Cenkos Securities.
Douglas A. McIntyre
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
